Home / The Issues / Hear From the Experts That Support Reform / An Interview with J. Thomas Rosenthal, MD
An Interview with J. Thomas Rosenthal, MD
Dr. Rosenthal is a retired Chief Medical Officer, UCLA Medical Center, Associate Vice Chancellor, David Geffen School of Medicine at UCLA, Director of the Kidney Transplant Program at UCLA and an esteemed Advisory Board member of SID&T.
The following videos are from an interview with J. Thomas Rosenthal, MD a nationally recognized expert on organ transplant.
Dr. Rosenthal on SID&T…
I joined the SID&T Advisory Board because the organization has proven itself over the years.
Dr. Rosenthal on the Governing Rule …
Reputable statisticians pointed out the rule’s flaws in its comment period years ago and CMS ignored their denominator mistake. NASEM reiterated the statistical findings.
Dr. Rosenthal on NASEM and joint commission type recommendations …
The 2022 NASEM study pointed out that OPOs are the only entity judged with single measure. I know from years of heading the UCLA Medical Center that the system needs Joint Commission type oversight.
Dr. Rosenthal HRSA censored data but everyone knows the Rule is fragile.
At the American Transplant Congress in June of 2024 everyone knew, despite HRSA censoring scheduled research abstracts, that the rule is fragile. CMS knows it can’t stand scrutiny. SID&T is collating informed voices. Dr. Rosenthal mentions the scientific voices being raised in 2008 against the metrics which happened widely in 2020 prior to the rule adoption.
Dr. Rosenthal on the history of CMS metrics failures …
CMS has failed at creating the proper performance measurements three times in the past, as SID&T enumerates on its website. They can either fix the rule or again have it thrown out on appeal.
Dr. Rosenthal on the NASEM study giving CMS a path forward.
CMS can (and must) do better. The NASEM study is a gift to CMS, as are the published research findings since 2020. The politics in Washington has to change.